| Registry | NCT07847151, acronym MIND-AMD |
|---|---|
| Status | Not yet recruiting |
| Study type | Observational |
| Enrollment | 160 (Estimated) |
| Sponsor | IRCCS San Raffaele (Other); collaborators: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Conditions | Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD), AMD Population - Intermediate or Advanced AMD, AMD and Macular Edema, Neovascular (Wet) Age-Related Macular Degeneration |
| Dates | start 2027-01-02 (estimated), primary completion 2029-06-30 (estimated), completion 2030-01-02 (estimated), first posted 2026-09-29, last updated 2026-09-29 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Age-Related (Dry) Macular Degeneration All trials for Age-Related Macular Degeneration (AMD)
Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage. However, it often evolves towards complicated stages, namely neovascular AMD or geographic atrophy (GA). Despite the available treatments, the visual outcome is highly heterogeneous. The scientific interest is growing regarding the assessment of neuroretinal changes in AMD. Although AMD is mainly considered an outer retinal disease, recent evidence suggests a major involvement of retinal glia and neurons, i.e. an involvement of the inner retina. This damage may remarkably affect the morphological and functional AMD outcome, subverting retinal signal transmission cascade and more clearly explaining the outcome of the disease. The main goal of this study is to perform a multidisciplinary, multicenter, both prospective and retrospective evaluation of neuroretinal degeneration in different AMD stages in preclinical and clinical models.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Patients affected by AMD (different stages) | Patients affected by intermediate, wet and dry atrophic AMD | ||
| Healthy controls | Healthy age- and gender-matched control |
Sex: All, ages: 50 Years to any, accepts healthy volunteers
Inclusion Criteria: * Confirmed diagnosis of AMD Exclusion Criteria: * low BCVA (<20/100) * other ocular diseases * uncontrolled systemic diseases potentially affecting data interpretation